What AFLURIA Treats: Main Uses and Benefits

This vaccine is generally used for active immunization to help reduce the chance of illness caused by specific seasonal influenza A and B viruses.

AFLURIA is commonly used for seasonal influenza, a condition characterized by symptoms that interfere with daily functioning, such as fever and fatigue. Its use is relevant for preventative care, contributing to supporting general well-being.

The vaccine assists in addressing conditions that produce significant symptomatic burden, such as viral pneumonia and the exacerbation of existing chronic conditions. For high-risk groups, this supports general well-being during symptomatic phases.

“The assistance provided helps maintain a sense of stability when symptoms are more noticeable.”

AFLURIA contributes to improved comfort during symptomatic periods and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Used for managing Flu Illness Potential

AFLURIA QUADRIVALENT is officially approved for use in persons 6 months of age and older, defining the minimum age threshold for administration.

---

Contraindicated Populations

The vaccine is contraindicated in individuals with a known severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any influenza vaccine.

---

Condition-Specific Eligibility Rules

• Acute Illness: Vaccination should be deferred in persons experiencing a moderate or severe acute illness until recovery.
• Neurological History (GBS): Individuals with a history of Guillain-Barré Syndrome (GBS) occurring within six weeks of a previous influenza vaccination are a population requiring conditional use. The decision to administer the vaccine must be based on a careful assessment of risks and benefits.

---

Age and Specific Populations

Category	Official Regulatory Status
Pediatric Use	Safety and effectiveness have not been established in persons less than 6 months of age.
Needle-Free System	Administration via the PharmaJet Stratis Needle-Free Injection System is restricted to persons 18 through 64 years of age only.
Pregnancy/Lactation	The regulatory label lists these as specific populations and notes the existence of a pregnancy exposure registry to monitor outcomes.

Regulatory documents define eligibility by establishing a clear minimum age and enforcing absolute contraindications based on specific allergic histories, while imposing temporary deferral rules for acute illness, structuring the conditional use requirements mandated by the authorities.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for AFLURIA QUADRIVALENT, based strictly on regulatory prescribing information.

Documented Interaction Patterns

Classification	Official Regulatory Statement
Pharmacodynamic Interaction	Immunosuppressive therapy may lead to a diminished immune response to the vaccine.
Population-Specific Note	The interaction is relevant for immunocompromised persons, who may not develop sufficient protective antibodies.

Co-administration and Procedural Requirements

Regulatory documents confirm that AFLURIA QUADRIVALENT can be administered concurrently with other vaccines, provided specific procedural constraints are followed. When administered simultaneously with other injectable vaccines, the procedure mandates the use of a separate syringe and a separate injection site (e.g., a different limb) for each product.

Pharmacokinetic and Substance Interactions

Official labeling does not report any clinically significant pharmacokinetic interactions, such as those mediated by cytochrome P450 enzymes or drug transport proteins. Furthermore, regulatory information does not document any mandatory restrictions or formal interactions with food, alcohol, or specific herbal products.

How AFLURIA Works

The mechanism of AFLURIA is based on actively engaging the body's adaptive immune response through specific molecular interactions.

Antigenic Introduction and Signaling

The vaccine contains inactivated hemagglutinin (HA) and neuraminidase (NA) proteins, which serve as the primary biological targets. The mechanism initiates when these non-replicating viral components are processed by antigen-presenting cells (APCs). This leads to the presentation of the viral surface targets, activating T-lymphocyte and B-lymphocyte cascades.

Humoral Response Pathway Modulation

This modulates signaling dynamics within the humoral immune pathways. Antigen presentation triggers the activation, proliferation, and differentiation of B-lymphocytes into plasma cells. This activity results in the synthesis of high levels of specific neutralizing antibodies, which are the main effector molecules in this response.

Viral Neutralization and Inhibition

The final mechanism involves the functional role of the generated antibodies. They physically bind to the hemagglutinin protein on the actual, live influenza virus. This targeted steric inhibition directly blocks the virus's ability to engage with host respiratory cell receptors, influencing subsequent steps of the viral entry pathway.

Administration Guidelines: How to use AFLURIA

AFLURIA is administered by intramuscular (IM) injection only. The vaccine can be given by a standard needle and syringe to all approved age groups (6 months and older). Additionally, in adults 18 through 64 years of age, it may be administered using the PharmaJet Stratis Needle-Free Injection System.

Preparation and Injection Site

Immediately before use, the vaccine must be shaken thoroughly and visually inspected for any particulate matter or discoloration. If the vaccine appears discolored or contains particles, it must not be administered. The correct injection site varies by age:

• Infants (6 through 11 months): Anterolateral aspect of the thigh.
• Children and Adolescents (12 months and older) and Adults: Deltoid muscle of the upper arm. The anterolateral thigh may also be used in persons 12 through 35 months of age if muscle mass is adequate.

Official Dosage and Schedule by Age

The dosage and schedule for AFLURIA are determined by the recipient's age and, for younger children, their prior vaccination history.

Age	Dose Volume	Schedule
6 months through 35 months	0.25 mL	One or two doses. If two doses are required, administer them at least 1 month apart.
36 months through 8 years	0.5 mL	One or two doses. If two doses are required, administer them at least 1 month apart.
9 years and older	0.5 mL	One dose.

Research Evidence / Overview of Studies for AFLURIA

Research for AFLURIA QUADRIVALENT was studied for the purpose of exploring the immune response against the four influenza virus strains it contains. The regulatory evaluation of the vaccine relies on evidence derived from formal clinical studies, including Randomized Controlled Trials (RCTs), and from large-scale observational studies that track patterns of use in real-world settings.

---

◡️ Evidence for Use in Preventing Seasonal Influenza

This section summarizes the core regulatory studies, primarily short-term RCTs, that research examined for the purpose of active immunization. Studies primarily evaluated Immunogenicity. This research describes the measurement of the body's creation of antibodies, specifically monitoring Hemagglutination Inhibition (HAI) antibody titers, which are outcomes related to systemic or functional imbalance. It also describes how studies explored the stimulation of antibody development against the four specified viral strains.

The studies were often active-controlled, meaning AFLURIA was evaluated in a comparison against another licensed influenza vaccine. Findings from these controlled trials described patterns where the measured immune responses—such as antibody levels—were consistent with the regulatory criteria for new flu vaccines across the general population. Data show patterns related to the expected immune reaction following vaccination.

---

Real-World Evidence and Clinical Effectiveness Measures

Beyond controlled settings, observational studies are used to provide estimates of how AFLURIA was associated with the outcome of laboratory-confirmed influenza illness during actual flu seasons. These studies focus on clinical outcomes reflecting daily functioning or activity level and outcomes describing episodic or acute changes.

---

Areas of Uncertainty and Research Limitations

A key limitation is the reliance on immunogenicity as the primary measure for regulatory approval, rather than direct data for preventing influenza illness in the controlled trials. Furthermore, evidence quality varies across studies. While high-quality RCTs describe an immune response, real-world effectiveness data comes from observational studies, where findings were mixed and subject to seasonal variability. These findings help contextualize what has been observed so far, but the evidence highlights what is known—and what is still uncertain—about the vaccine's performance outside of controlled trial conditions.

Key Studies & References

1. Quadrivalent Vaccines for the Immunization of Adults against Influenza: A Systematic Review of Randomized Controlled Trials (MDPI)

Common questions about AFLURIA (FAQ)

---

Q: How quickly does AFLURIA start working after it is administered?

Official guidance indicates that it generally takes about two weeks (10 to 14 days) for antibodies to develop following vaccination. This response prepares the body’s immune system to recognize the flu virus.

---

Q: What is the average duration of protection offered by AFLURIA?

Protection is generally considered to last throughout one influenza season. A new vaccine is typically administered every year because immune protection may decline over time, and the circulating virus strains can change annually.

---

Q: Does AFLURIA contain antibiotics like gentamicin or neomycin?

The official product information indicates that the vaccine may contain trace residual amounts of certain substances, such as neomycin and polymyxin B sulfate, which are used during the manufacturing process. These are not active ingredients of the vaccine.

---

Q: What is the difference between AFLURIA and high-dose flu shots?

AFLURIA is classified as a standard-dose vaccine. High-dose flu shots are distinct products licensed specifically for persons aged 65 years and older. The key difference is the amount of antigen (the active component) they contain, with high-dose versions having a higher amount per strain compared to standard doses.

---

Q: Why is AFLURIA sometimes preferred over other flu vaccine brands?

Regulatory documents note a distinguishing feature: AFLURIA is one of the standard-dose vaccines approved for administration using the PharmaJet Stratis Needle-Free Injection System. This option is listed for use in adults aged 18 through 64 years.

---

Q: Does the formula for AFLURIA change every year?

Yes, the formula for AFLURIA is designed to change annually. The World Health Organization (WHO) and other regulatory bodies review circulating influenza virus strains and update the formula each year to include the strains predicted to be most common during the upcoming flu season.

---

Q: Can people with certain autoimmune conditions use AFLURIA?

Regulatory documents state that the effectiveness of AFLURIA may be diminished in people who are immunocompromised. The use of the vaccine in individuals with compromised immune systems is evaluated based on the specific condition.

---

Q: Is there a different formulation of AFLURIA for people 65 years and older?

AFLURIA is a standard-dose, quadrivalent inactivated vaccine. While the manufacturer markets other specific products that are adjuvanted for use in people 65 years and older, the AFLURIA brand itself is not a high-dose or adjuvanted formulation.

---

Q: What is the shelf life or typical expiration period of AFLURIA?

AFLURIA has a specific expiration date printed on its packaging, which is determined by the manufacturer based on stability testing. The product should not be used past this date, as this may affect the expected potency of the vaccine.

---

Q: What does 'use conditions' mean for AFLURIA in the product label?

The term 'use conditions' in the official product label refers to the officially approved aspects of the medicine. This includes the approved uses (Indication and Usage), the minimum age threshold for administration, and the required route and method of administration.

---

Q: Can a history of severe fainting after a shot prevent someone from receiving AFLURIA?

Fainting (syncope) can occur after any injection, including AFLURIA. While syncope is not an official contraindication, the safety information notes that the risk of dizziness or fainting is highest immediately after the vaccine is administered.

---

Q: What is the role of the World Health Organization (WHO) in determining the components of AFLURIA?

The World Health Organization (WHO) plays a crucial advisory role by annually recommending the influenza virus strains to be included in vaccines. This guidance is then used by national regulatory agencies to finalize the formula for AFLURIA.

---

Q: Are there any restrictions on activity level after receiving AFLURIA?

There are no mandatory restrictions on activity level listed in the product label. However, common side effects such as pain, fatigue, and muscle aches typically resolve within one to three days, and activity may be limited by these temporary effects.

---

Q: Does AFLURIA contain latex or rubber components?

Product packaging must be consulted to check for specific latex or rubber components, as this can vary by the specific presentation, such as the syringe tip or plunger.

---

Q: Does AFLURIA contain any mercury or thimerosal?

The single-dose pre-filled syringe presentation of AFLURIA is thimerosal-free. Thimerosal, which acts as a preservative, is only present in the multi-dose vial presentation of the vaccine.

---

Q: Can a pregnant person receive AFLURIA?

Official health guidance states that inactivated influenza vaccines are generally considered appropriate for use during any trimester of pregnancy. The regulatory label for AFLURIA lists pregnancy as a specific population and notes the existence of a Pregnancy Exposure Registry to monitor outcomes.

---

Q: What are the main ingredients listed in AFLURIA besides the active components?

Inactive ingredients can include salts (such as sodium chloride), sucrose, and ovalbumin (egg protein). Trace residuals of substances like neomycin or polymyxin B may also be present, and thimerosal is included in multi-dose vials.

---

Q: What are the general population groups that official agencies recommend AFLURIA for?

Official health agencies state that annual vaccination against influenza is appropriate for everyone 6 months of age and older who does not have a contraindication.

---

Q: Can AFLURIA be used by people who are breastfeeding?

The regulatory label notes that it is not known whether AFLURIA passes into breast milk. The use of the vaccine in breastfeeding individuals is typically handled on a case-by-case basis.

---

Q: Is it normal to have redness or swelling at the injection site after AFLURIA?

Yes, local reactions such as redness, swelling, and pain at the injection site are among the most commonly reported adverse reactions observed in clinical trials. These effects are usually mild and resolve spontaneously within one to three days.

---

Q: Are there any religious or dietary concerns related to the components of AFLURIA?

As an egg-derived vaccine, AFLURIA may contain trace amounts of egg protein (ovalbumin). Individuals with specific dietary or religious concerns can consult the full list of ingredients in the product information.

---

Q: What information exists about the use of AFLURIA in people with chronic illnesses?

Individuals with certain underlying chronic health conditions or weakened immune systems are often at a greater risk of flu complications, and vaccination is generally considered appropriate. However, the use of the vaccine in people taking immunosuppressive therapies may lead to a diminished immune response.

---

Q: How do regulatory bodies classify the safety profile of AFLURIA?

Regulatory documents classify the safety profile by explicitly listing absolute contraindications, such as a severe allergic reaction to components. They also detail warnings regarding specific rare neurological conditions and provide special safety considerations for specific populations.

---

Q: Do people who have had the flu before still need to receive AFLURIA?

Yes. A previous influenza infection may only provide immunity against the specific virus strain that caused the illness. Since the flu strains change and protection wanes, an annual flu vaccine is appropriate to provide current protection.

How to Store and Dispose of AFLURIA and AFLURIA QUADRIVALENT

AFLURIA and AFLURIA QUADRIVALENT must be stored refrigerated between 2 C and 8 C (36 F and 46 F). It is mandatory not to freeze the vaccine; the product must be discarded if it has been frozen, as freezing destroys potency. The product requires protection from light and must remain in its original container until use.

Storage Restriction	Requirement
Temperature	2 C to 8 C
Freezing	Do not freeze
Light	Protect from light

Multi-dose vials should not exceed 20 needle punctures and must be immediately returned to refrigeration between uses. All unused or expired vaccine must be disposed of according to federal, state, and local regulations. Multi-dose vials contain thimerosal and are classified as federally hazardous waste (D009) unless testing confirms otherwise. Keep the medicine out of the reach of children.